In this episode, David Flores talks with Sherry Rais of Enthea to discuss Enthea’s very unique objective of helping employers optimize happiness and health within their workplace by integrating ketamine therapy as an add-on to their existing employee health benefit programs.
NEW BUY RATINGS, More Partnerships and Government Awards for psychedelic inspired companies! In this episode, we’ll take a look at the smaller psychedelic medicine companies such as Mydecine, Entheon Biomedical, Braxia, Small Pharma, Silo Therapeutics and Bright Minds Sciences.
Enjoy the episode!
Timestamps:
0:00 – Intro
0:44 – Mydecine (MYCO/ MYCOF) Unveils Artificial Intelligence Drug Discovery Program
2:21 – Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression
3:51 – Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO)
6:59 – Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq
8:43 – Small Pharma (TSXV: DMT) – Price Target of C$5
Links:
Mydecine (OTC: MYCOF, NEO: MYCO) Unveils Artificial Intelligence Drug Discovery Program, in conjunction with the University of Alberta:
https://www.psychedelicfinance.com/articles/mydecine-unveils-artificial-intelligence-drug-discovery-program
Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression:
https://braxiascientific.com/news/braxia-scientific-awarded-government-of-canada-funding-to-complete-first-of-its-kind-ketamine-clinical-trial-for-bipolar-depression/
Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO):
https://thecannabisstock.com/2021/06/17/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-and-silo-wellness-announces-psychedelics-genetic-test-kit-partnership/
Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq:
https://psilocybinalpha.com/news/bright-minds-biosciences-announces-application-to-list-on-nasdaq
Small Pharma (TSXV: DMT) – Roth Capital Initiates Coverage On Small Pharma with Buy Rating, Announces Price Target of C$5:
https://www.benzinga.com/news/21/06/21452074/roth-capital-initiates-coverage-on-small-pharma-with-buy-rating-announces-price-target-of-c-5
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Website: https://thepsychedelicinvestor.com/
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Mydecine #Entheon #MYCO
Buy your tickets to the Benzinga Psychedelics Capital Conference on…
During our time in Wonderland Miami, we had the pleasure to meet and interview Dr. Matthew Johnson of Johns Hopkins University. In this Psychedelic Spotlight Interview, we discuss a wide range of topics surrounding psychedelics and their effectiveness as treatments for ailments like tobacco addiction and PTSD. Of course, our conversation took as spin as we also touched on topics such as UFOs, DMT experiences and the CIA!
Timestamps:
0:00 – Intro
1:10 – Dr. Johnson’s latest updates on treating smoking cessation with psilocybin
6:55 – MAPS’ study using MDMA to treat PTSD
7:20 – DMT’S mystical experiences of perceiving aliens, machine elves and autonomous beings
13:08 – CIA research on psychedelics for telepathy and remote viewing
15:01 – What is consciousness?
19:02 – The intriguing evidence of UFOs?
21:40 – Where do we see psychedelics going in the next 5 years?
Make sure to like, share and subscribe if you enjoyed this episode!
#Psychedelics #MatthewJohnson #UFO
On this episode of the Psychedelic Spotlight Podcast, our host David Flores catches up with former Philadelphia Flyer and NHL enforcer, Riley Cote who in recent years has become one of the most prominent and outspoken advocates for psychedelics and psychedelic-assisted therapy through his work with the Wake Network and RileyCote.com.
In this conversation, David and James discuss the great deal of work that Mindset has done to set the stage for the launch of one or more drug candidates into first in-human clinical trials in 2023.
Tim Moore, CEO of Havn Life discusses how he is leveraging his past experience in the cannabis industry to create an effective path to success for Havn Life.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
